Objective： To understand the relationship between C-erbB-2 and multidrug resistance （MDR） as well as its clinical significance. Methods： P-gp level was detected by flow cytometry and simultaneously to examine the ...Objective： To understand the relationship between C-erbB-2 and multidrug resistance （MDR） as well as its clinical significance. Methods： P-gp level was detected by flow cytometry and simultaneously to examine the C-erbB-2 expression level by immunohistochemistry assay in the operating samples. Their relationship was analyzed from 59 cases with gastric carcinoma. Results： The P-gp positive expression was 38/59 （64.4%） cases with gastric carcinoma. The C-erbB-2 positive expression was 21/59 （35.6%） cases with gastric carcinoma. From the analysis of the P-gp and C-erbB-2 relationship, which was involving, range in the gastric carcinoma, that involving two or three sites were more than the site one, in the cases with C-erbB-2 negative. Compared this two groups, there was a significant difference （P = 0.026）. When the C-erbB-2 was positive, the P-gp expression had a significant difference （P = 0.04） in comparing the Ⅲ-Ⅳ stage （lymph node metastasis） with Ⅰ-Ⅱ stage （without lymph node metastasis）. The tumor＇s size, differentiation degree, ages and sex were not related to the C-erbB- 2 and P-gp expression. Conclusion： High level of P-gp expression was related to the C-erbB-2 positive expression in clinical Ⅲ-Ⅳ stage patient with gastric carcinoma （lymph node metastasis）. It suggested that the double positive patient might be a poor prognosis. However, when the C-erbB-2 was negative expression, the clinical staging （with lymph node metastasis） was not related to the P-gp expression in gastric carcinoma patients.展开更多
基金the Zhejiang Medical and Health Science Foundation (No. 2005A09)
文摘Objective： To understand the relationship between C-erbB-2 and multidrug resistance （MDR） as well as its clinical significance. Methods： P-gp level was detected by flow cytometry and simultaneously to examine the C-erbB-2 expression level by immunohistochemistry assay in the operating samples. Their relationship was analyzed from 59 cases with gastric carcinoma. Results： The P-gp positive expression was 38/59 （64.4%） cases with gastric carcinoma. The C-erbB-2 positive expression was 21/59 （35.6%） cases with gastric carcinoma. From the analysis of the P-gp and C-erbB-2 relationship, which was involving, range in the gastric carcinoma, that involving two or three sites were more than the site one, in the cases with C-erbB-2 negative. Compared this two groups, there was a significant difference （P = 0.026）. When the C-erbB-2 was positive, the P-gp expression had a significant difference （P = 0.04） in comparing the Ⅲ-Ⅳ stage （lymph node metastasis） with Ⅰ-Ⅱ stage （without lymph node metastasis）. The tumor＇s size, differentiation degree, ages and sex were not related to the C-erbB- 2 and P-gp expression. Conclusion： High level of P-gp expression was related to the C-erbB-2 positive expression in clinical Ⅲ-Ⅳ stage patient with gastric carcinoma （lymph node metastasis）. It suggested that the double positive patient might be a poor prognosis. However, when the C-erbB-2 was negative expression, the clinical staging （with lymph node metastasis） was not related to the P-gp expression in gastric carcinoma patients.
